Zacks Research Analysts Increase Earnings Estimates for Teleflex Incorporated (NYSE:TFX)

Teleflex Incorporated (NYSE:TFXFree Report) – Zacks Research upped their Q4 2024 EPS estimates for shares of Teleflex in a research note issued to investors on Wednesday, September 25th. Zacks Research analyst R. Department now expects that the medical technology company will post earnings per share of $3.88 for the quarter, up from their previous estimate of $3.87. The consensus estimate for Teleflex’s current full-year earnings is $13.97 per share. Zacks Research also issued estimates for Teleflex’s Q1 2025 earnings at $3.47 EPS, Q3 2025 earnings at $3.90 EPS, Q4 2025 earnings at $4.25 EPS and Q1 2026 earnings at $3.98 EPS.

A number of other brokerages have also commented on TFX. Truist Financial lifted their price target on shares of Teleflex from $240.00 to $247.00 and gave the stock a “hold” rating in a report on Monday, August 5th. Piper Sandler raised shares of Teleflex from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $205.00 to $245.00 in a research note on Monday, July 1st. Stephens lifted their price target on shares of Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Royal Bank of Canada lifted their price target on shares of Teleflex from $235.00 to $260.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Teleflex presently has a consensus rating of “Moderate Buy” and a consensus price target of $265.57.

View Our Latest Research Report on TFX

Teleflex Price Performance

Shares of NYSE:TFX opened at $246.83 on Friday. The firm has a market cap of $11.63 billion, a PE ratio of 39.62, a price-to-earnings-growth ratio of 2.23 and a beta of 1.16. The firm’s fifty day moving average is $237.48 and its 200-day moving average is $221.22. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 2.58. Teleflex has a 52 week low of $177.63 and a 52 week high of $257.85.

Teleflex (NYSE:TFXGet Free Report) last issued its earnings results on Thursday, August 1st. The medical technology company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.33 by $0.09. Teleflex had a net margin of 8.76% and a return on equity of 14.51%. The firm had revenue of $749.70 million for the quarter, compared to analyst estimates of $762.98 million. During the same quarter last year, the business posted $3.41 earnings per share. The company’s quarterly revenue was up .9% on a year-over-year basis.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC purchased a new position in Teleflex during the second quarter worth about $918,000. Next Capital Management LLC boosted its stake in Teleflex by 7.0% in the second quarter. Next Capital Management LLC now owns 10,414 shares of the medical technology company’s stock valued at $2,190,000 after acquiring an additional 685 shares during the last quarter. Kimelman & Baird LLC purchased a new position in Teleflex in the second quarter valued at about $21,232,000. Quarry LP purchased a new position in Teleflex in the second quarter valued at about $48,000. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in Teleflex by 19.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 484 shares of the medical technology company’s stock valued at $102,000 after acquiring an additional 80 shares during the last quarter. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Teleflex

In other news, Director Stuart A. Randle sold 2,674 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $238.93, for a total transaction of $638,898.82. Following the completion of the sale, the director now directly owns 5,496 shares of the company’s stock, valued at $1,313,159.28. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.43% of the stock is currently owned by insiders.

Teleflex Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Thursday, August 15th were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 0.55%. The ex-dividend date of this dividend was Thursday, August 15th. Teleflex’s payout ratio is presently 21.83%.

Teleflex Company Profile

(Get Free Report)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

Further Reading

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.